MediWound Ltd.

Equities

MDWD

IL0011316309

Pharmaceuticals

Real-time Estimate Cboe BZX 10:46:53 2024-03-28 am EDT 5-day change 1st Jan Change
14.71 USD -2.58% Intraday chart for MediWound Ltd. -4.70% +49.46%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024
MediWound Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (MDWD) MEDIWOUND Posts Q4 Revenue $5.3M, vs. Street Est of $5.3M MT
MediWound Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Sector Update: Health Care Stocks Mixed Late Afternoon MT
MediWound Shares Rise After Positive Results From EscharEx Comparison Study MT
Mediwound Ltd. Announces Positive Results in Head-To-Head Comparison of Escharex® Vs. Santyl® Within the Chronex Phase Ii Randomized Controlled Study CI
MediWound's NexoBrid Application to Include Pediatric Patients Accepted for Review by FDA MT
Mediwound Announces That FDA Has Accepted for Review the Supplement to the Nexobrid BLA to Include Pediatric Patients with Severe Thermal Burns CI
MediWound Secures $6.7 Million in DoD Funding for Field Burn Treatment Therapy MT
Mediwound Ltd. Secures Additional U.S. Department of Defense Funding to Advance Nexobrid® Development for the U.S. Army CI
Mediwound Ltd. Announces Publication of Escharex Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads CI
Transcript : MediWound Ltd., Q3 2023 Earnings Call, Nov 21, 2023
Earnings Flash (MDWD) MEDIWOUND Reports Q3 Revenue $4.8M, vs. Street Est of $4.8M MT
MediWound Ltd. Appoints Shmulik Hess as Chief Operating Officer and Chief Commercial Officer, Effective December 1, 2023 CI
MediWound Wins European Agency Approval for NexoBrid Expansion to All Age Groups in Deep Thermal Burn Cases MT
MediWound Ltd Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients CI
MediWound, PolyMedics Innovations Sign Agreement to Promote NexoBrid in Europe MT
MediWound Ltd. Announces Collaboration with PolyMedics Innovations for NexoBrid Distribution in Europe CI
MediWound Collaborates With 3M Unit on Drug Candidate EscharEx Late-Stage Study MT
MediWound Deploys Emergency Supply of NexoBrid to Help Burn Victims in Israel MT
MediWound Ltd. Deploys NexoBrid® for Emergency Supply CI
MediWound Receives $6.5 Million Funding From Defense Department to Develop Burn Treatment for US Army MT
MediWound Ltd. Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army CI
HC Wainwright Adjusts Price Target on MediWound to $26 From $23, Keeps Buy Rating MT
Chart MediWound Ltd.
More charts
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
15.1 USD
Average target price
28.5 USD
Spread / Average Target
+88.74%
Consensus
  1. Stock
  2. Equities
  3. Stock MediWound Ltd. - Nasdaq
  4. News MediWound Ltd.
  5. Earnings Flash (MDWD) MEDIWOUND Reports Q1 Loss $-0.12, vs. Street Est of $-0.11